We are live on ! Find out more
VNRX icon

VolitionRx

18 hedge funds and large institutions have $13.4M invested in VolitionRx in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.46% less ownership

Funds ownership: 17.61% → 17.15% (-0.46%)

5% less funds holding

Funds holding: 19 → 18 (-1)

25% less capital inflows, than outflows

Capital inflows: $827K | Capital outflows: $1.11M

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.41%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VNRX Hedge Fund Activity: Q4 2017 in Review

18 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in VolitionRx (VNRX) for Q4 2017, worth a combined $13.4M — up 8.6% from $12.3M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of VNRX and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.

The largest buyer was Lagoda Investment Management, adding an estimated $469K. The largest seller was Southpoint Capital Advisors, exiting entirely with an estimated $698K sold.

  • 18 institutional investors held VolitionRx (VNRX) as of Q4 2017, down from 19 in Q3 2017.
  • Funds reported $13.4M of VolitionRx stock for Q4 2017, up 8.6% quarter-over-quarter.
  • 2 funds opened new VolitionRx positions in Q4 2017 and 3 closed out, a net change of -1 holder.
  • The largest VolitionRx buyer in Q4 2017 was Lagoda Investment Management, an estimated $469K added.
  • The largest VolitionRx seller in Q4 2017 was Southpoint Capital Advisors, an estimated $698K sold.

Based on aggregated 13F filings for Q4 2017.